Overview
DITRA stands for Deficiency of Interleukin-36 Receptor Antagonist. It is a rare genetic skin condition that causes repeated, severe flares of generalized pustular psoriasis. In this disease, the body's immune system becomes overactive because it lacks a natural brake called the interleukin-36 receptor antagonist (IL-36Ra). Without this brake, inflammation spirals out of control, leading to widespread painful skin eruptions covered with tiny pus-filled bumps (pustules), along with high fever, extreme fatigue, and a general feeling of being very unwell. During flares, large areas of the skin become red, swollen, and covered with sheets of sterile pustules. The skin can become very tender and may peel off in sheets. These episodes can be life-threatening if not treated promptly, as patients may develop dangerous complications including infections, organ failure, and severe dehydration. Flares can be triggered by infections, stress, pregnancy, or stopping certain medications, though sometimes they occur without a clear trigger. Treatment has improved significantly in recent years. Historically, doctors used broad immunosuppressive drugs like cyclosporine, methotrexate, retinoids (acitretin), and systemic corticosteroids to control flares, though these had significant side effects. A major breakthrough came with spesolimab (Spevigo), an FDA-approved medication that specifically blocks the interleukin-36 pathway. This targeted therapy can rapidly control flares and represents a game-changer for patients with DITRA. Supportive care during flares, including fluid replacement and skin care, remains important.
Also known as:
Key symptoms:
Widespread red, inflamed skinSheets of tiny pus-filled bumps covering large areas of the bodyHigh fever during flaresExtreme tiredness and feeling very unwellSkin peeling off in large sheetsPainful, tender skinChills and shiveringSwollen and painful jointsElevated white blood cell countNail changes or nail lossBurning or stinging sensation on the skinDehydration during severe flaresSwelling of the legs or feetRecurrent episodes that come and go
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
10 eventsCaja Costarricense de Seguro Social
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — PHASE2
Bristol-Myers Squibb
Shanghai Huaota Biopharmaceutical Co., Ltd. — PHASE2, PHASE3
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — PHASE1
Takeda — PHASE3
Janssen Pharmaceutical K.K. — PHASE3
Boehringer Ingelheim — PHASE4
Innovaderm Research Inc.
CorEvitas
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
1 availableKineret
treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to DITRA.
Community
No community posts yet. Be the first to share your experience with DITRA.
Start the conversation →Latest news about DITRA
Disease timeline:
New recruiting trial: A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
A new clinical trial is recruiting patients for DITRA
New recruiting trial: Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
A new clinical trial is recruiting patients for DITRA
New recruiting trial: Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
A new clinical trial is recruiting patients for DITRA
New recruiting trial: CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
A new clinical trial is recruiting patients for DITRA
New recruiting trial: Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
A new clinical trial is recruiting patients for DITRA
New recruiting trial: Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
A new clinical trial is recruiting patients for DITRA
New recruiting trial: A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
A new clinical trial is recruiting patients for DITRA
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Is spesolimab (Spevigo) available and appropriate for my case, and how do I access it?,What should I do at the first sign of a flare — is there a step-by-step emergency plan?,What triggers should I try to avoid, and are there known factors that make flares more likely?,What is the long-term plan to prevent future flares, and what maintenance therapy options exist?,Should my family members be tested for the IL36RN gene mutation?,What are the risks and side effects of the recommended treatments?,How will this condition affect pregnancy planning, and what treatments are safe during pregnancy?
Common questions about DITRA
What is DITRA?
DITRA stands for Deficiency of Interleukin-36 Receptor Antagonist. It is a rare genetic skin condition that causes repeated, severe flares of generalized pustular psoriasis. In this disease, the body's immune system becomes overactive because it lacks a natural brake called the interleukin-36 receptor antagonist (IL-36Ra). Without this brake, inflammation spirals out of control, leading to widespread painful skin eruptions covered with tiny pus-filled bumps (pustules), along with high fever, extreme fatigue, and a general feeling of being very unwell. During flares, large areas of the skin be
How is DITRA inherited?
DITRA follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for DITRA?
Yes — 9 recruiting clinical trials are currently listed for DITRA on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat DITRA?
10 specialists and care centers treating DITRA are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.